|
|
Navigating IBS: From Symptoms to Solutions
|
|
Facebook
LinkedIn
E-Mail
|
(5367)
|
Released: 09/25/2024
Expires: 09/30/2025 (subject to change)
- CE for this activity will not be available after this date.
 | This activity includes closed captioning. |
| Delivery Note: The content for this activity was previously presented during the 2024 AANP Fall Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies. |
Overview
Despite its widespread prevalence and significant impact on patient quality of life, irritable bowel syndrome (IBS) has historically been relegated to the ambiguity of “stomach trouble,” in part due to societal stigma and patient reticence to report symptoms, and in part due to the general lack of scientific knowledge of its etiology and pathophysiology. Kim and Christina will help the audience navigate through the identification, diagnosis and treatment options for IBS.
Objectives - Describe the pathophysiologic fundaments of irritable bowel syndrome (IBS).
- Review expert consensus best practices for diagnosing and characterizing IBS.
- Identify standard-of-care treatment pathways for patients with IBS-C and IBS-D.
- Implement patient-centric IBS management using shared decision-making.
Speakers
Christina Hanson, FNP-C
Kimberly Kearns, MS, ANP-BC
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.The speakers have the following disclosures:
- Christina Hanson
- Speaker Bureau: Salix (IBS-D, HE), Intercept (PBC), Madrigal (MASH), Phathom (EE, NERD, H. Pylori), Sanofi/Regeneron (EoE), Novo Nordisk (MASH), Ardelyx (IBS-C), Ipsen (PBC)
- Advisory Boards: Salix, Ipsen, Madrigal, Phathom, Intercept, Sanofi/Regeneron, Novo Nordisk, Exact Sciences
- Kimberly Kearns
- Speaker Bureau: Eli Lilly (IBD), Janssen (IBD), Nestlé Health Science, (C-diff), Salix (IBS, CIC) and Takeda Pharmaceuticals (IBD)
- Advisory Boards: Ardelyx (IBS), Eli Lilly (IBD), Bristol Meyer Squibb (IBD), Janssen (IBD), Salix (IBS and CIC) and Pfizer Pharmaceuticals (IBD)
- Consultant: Janssen Pharmaceuticals and Takeda Pharmaceuticals for (IBD)
All relevant financial relationships have been mitigated.All Planners involved in this activity have no relevant financial relationships to disclose. This continuing education activity is supported by an independent medical education grant from Salix and Ardelyx.
This presentation was first presented as a Live event at AANPs 2024 Fall Conference in Reno, NV and pre-recorded for this on-demand presentation.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content:
- Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test.
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1 Contact Hour(s) of CE,
0.5 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
